A. F. Tsyb Medical Radiological Research Center, Affiliated Branch of the National Medical Research Radiological Center, Ministry of Health of the Russian Federation, Obninsk, Russia.
Bull Exp Biol Med. 2020 Feb;168(4):561-565. doi: 10.1007/s10517-020-04753-5. Epub 2020 Mar 9.
Experiments on F1(CBA×C57BL/6) mice with experimental metastatic melanoma B16 F10 showed that single intravenous injection of xenogeneic bone marrow mesenchymal stromal cells (BM-MSC) in a dose of 10 cells/mouse significantly increased 100-day survival rate of tumor-bearing animals. In contrast, administration of BM-MSC in a dose of 2×10 cells/ mouse reduced survival rates in comparison with the biocontrol (injection of B16 cells alone, 5×10 cells/mouse). This phenomenon can be related to in vivo participation of BM-MSC in reprogramming of resident tissue macrophages, including tumor microenvironment, towards pro- (M1) or anti-inflammatory (M2) phenotype. This is indirectly confirmed by the data on switching from activation to inhibition of ROS-producing activity of blood mononuclears and peritoneal macrophages in tumor-bearing mice in the test of luminol-dependent zymosaninduced chemiluminescence.
实验研究表明，F1（CBA×C57BL/6）小鼠实验性转移性黑色素瘤 B16 F10 模型中，单次静脉注射 10 个细胞/只的异种骨髓间充质基质细胞（BM-MSC）可显著提高荷瘤动物的 100 天存活率。相比之下，与生物对照（单独注射 5×10 个细胞/只 B16 细胞）相比，2×10 个细胞/只的 BM-MSC 给药降低了存活率。这种现象可能与 BM-MSC 在体内参与常驻组织巨噬细胞（包括肿瘤微环境）的重编程有关，使其向促炎（M1）或抗炎（M2）表型转化。这一点可通过化学发光测定法中洛氨酸依赖性酵母聚糖诱导的化学发光实验中，荷瘤小鼠血液单核细胞和腹腔巨噬细胞的 ROS 产生活性从激活向抑制的转变数据间接证实。
